Initial Pharmacotherapy for Adults with Newly Diagnosed ADHD

First-Line Treatment Selection

The American Academy of Child and Adolescent Psychiatry recommends starting with a stimulant medication, specifically methylphenidate or amphetamine formulations, as first-line treatment for adults with ADHD, due to their superior efficacy and rapid onset of action 1
Stimulants are the recommended first-line pharmacological intervention for adult ADHD based on their extensive evidence base and superior efficacy compared to non-stimulants, with both methylphenidate and amphetamine formulations being appropriate initial choices 1, 2

For methylphenidate formulations in adults, start with 5-10 mg in the morning after breakfast, and titrate gradually by 5-10 mg increments weekly based on response and tolerability 2
The maximum dose of methylphenidate typically ranges from 60-72 mg/day depending on formulation 1

For amphetamine-based medications, begin with 10 mg once daily in the morning, and increase by 5 mg weekly increments as needed, with a maximum recommended dose of 50 mg daily for adults 3

Before initiating stimulant therapy, evaluate cardiovascular screening, including baseline blood pressure, pulse, and assessment for symptomatic cardiovascular disease, as stimulants are contraindicated in patients with symptomatic heart disease 2
Screen for current or past substance abuse, as this represents a relative contraindication requiring close supervision, and consider non-stimulant alternatives in patients with active substance use disorders 2, 4, 5

Assess both therapeutic response and adverse effects at each dose adjustment, with follow-up appointments at least monthly until symptoms stabilize, using standardized rating scales to objectively measure improvement 3
Common adverse effects requiring monitoring include decreased appetite, gastrointestinal symptoms, sleep disturbances, and cardiovascular effects such as increased blood pressure and heart rate 2, 3, 5

If the first stimulant trial fails, switch to an alternative stimulant formulation before moving to non-stimulants, and consider non-stimulant medications such as atomoxetine or alpha-2 agonists as second-line options 1, 5
Atomoxetine is the primary non-stimulant alternative, initiated at 40 mg/day and titrated to a maximum of 100 mg/day, with a slower onset of action and no abuse potential 5

Do not start at excessively high doses, as this increases adverse effects and reduces adherence, and begin conservatively, especially in older patients who may have age-related increased sensitivity to both therapeutic and adverse effects 3
Allow adequate time between dose adjustments, minimum one week, to properly evaluate response before escalating 3

Long-acting formulations of methylphenidate, such as OROS methylphenidate, provide 8-12 hours of symptom control and are superior for maintaining adherence compared to immediate-release formulations, according to the American Academy of Child and Adolescent Psychiatry 6

The American Academy of Child and Adolescent Psychiatry recommends scheduling monthly visits until symptoms stabilize, assessing both therapeutic response and adverse effects at each dose adjustment using standardized rating scales 7
When combining clonidine with stimulants, the American Academy of Child and Adolescent Psychiatry suggests starting with 0.05 mg at bedtime and increasing slowly, never exceeding 0.3 mg/day 7
A full medical history of the patient and first-degree family members should be taken before starting clonidine, as a history of sudden death, repeated fainting, or arrhythmias may rule out its use, as advised by the American Academy of Child and Adolescent Psychiatry 7
The American Academy of Child and Adolescent Psychiatry advises against discontinuing stimulants abruptly for "drug holidays" during important events, as symptoms return rapidly upon discontinuation 7
The American Academy of Child and Adolescent Psychiatry recommends avoiding combining bupropion with stimulants until further safety data are available 7
Afternoon doses of methylphenidate may need to be higher than morning doses to prevent symptom attenuation later in the day, according to the American Academy of Child and Adolescent Psychiatry 6

The American College of Obstetricians and Gynecologists recommends starting with 150 mg once daily in the morning 8
The American College of Obstetricians and Gynecologists suggests titrating to a maintenance dose of 150-300 mg daily based on response and tolerability 8
The maximum dose is 450 mg per day, as recommended by the American College of Obstetricians and Gynecology 8

Bupropion is a second-line, non-stimulant alternative when stimulants are contraindicated, not tolerated, or ineffective, according to Pharmacology and Therapeutics 9
Stimulants remain first-line treatment for adult ADHD due to superior efficacy and rapid onset, as stated by Pharmacology and Therapeutics 9

The American College of Obstetricians and Gynecologists advises screening for seizure risk factors, as bupropion lowers seizure threshold 8
The American College of Obstetricians and Gynecologists recommends avoiding the use of bupropion in patients with eating disorders, seizure history, or abrupt alcohol/benzodiazepine withdrawal due to increased seizure risk 8